Schrodinger (NASDAQ:SDGR) said second-quarter annual contract value growth accelerated as demand broadened across large pharmaceutical customers, biotechnology companies and materials-science customers, while the company launched early access for Bunsen, its agentic AI co-scientist. Second-quarter
Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
319last 24h
2136last 7d
380● bullish (7d)
184● bearish (7d)
204publishers
MarketBeat7d agoneutral
Schrodinger Q2 Earnings Call HighlightsMoby98d agoneutral
Schrödinger, Inc. Q1 2026 Earnings Call SummaryMoby summary of Schrödinger, Inc.'s Q1 2026 earnings call
MarketBeat99d agoneutral
Schrodinger Q1 Earnings Call HighlightsSchrodinger (NASDAQ:SDGR) reported first-quarter 2026 results and highlighted progress in its transition to hosted software licensing, growth in annual contract value (ACV), and recent business development activity tied to its drug discovery collaborations. First-quarter metrics and hosted transiti